Novel Insights in Venous Thromboembolism Risk Assessment Methods in Ambulatory Cancer Patients: From the Guidelines to Clinical Practice

Anca Drăgan,Adrian Ştefan Drăgan

DOI: https://doi.org/10.3390/cancers16020458

2024-01-22

Cancers

Abstract:Many cancer patients will experience venous thromboembolism (VTE) at some stage, with the highest rate in the initial period following diagnosis. Novel cancer therapies may further enhance the risk. VTE in a cancer setting is associated with poor prognostic, a decreased quality of life, and high healthcare costs. If thromboprophylaxis in hospitalized cancer patients and perioperative settings is widely accepted in clinical practice and supported by the guidelines, it is not the same situation in ambulatory cancer patient settings. The guidelines do not recommend primary thromboprophylaxis, except in high-risk cases. However, nowadays, risk stratification is still challenging, although many tools have been developed. The Khrorana score remains the most used method, but it has many limits. This narrative review aims to present the current relevant knowledge of VTE risk assessment in ambulatory cancer patients, starting from the guideline recommendations and continuing with the specific risk assessment methods and machine learning models approaches. Biomarkers, genetic, and clinical features were tested alone or in groups. Old and new models used in VTE risk assessment are exposed, underlining their clinical utility. Imaging and biomolecular approaches to VTE screening of outpatients with cancer are also presented, which could help clinical decisions.

oncology

What problem does this paper attempt to address?

The main problems that this paper attempts to solve are: How to accurately assess the risk of venous thromboembolism (VTE) in outpatient cancer patients and provide a basis for deciding whether to carry out primary prevention in clinical practice. Specifically, the article explores the limitations of existing guidelines for VTE risk assessment and the application potential of new methods and technologies (such as biomarkers, imaging screening, and machine - learning algorithms).

### Main problem decomposition

1. **Limitations of existing guidelines**:
- Current guidelines mainly provide clear thromboprophylaxis strategies for hospitalized and surgical cancer patients.
- For outpatient cancer patients, the guidelines only recommend primary prevention for high - risk patients, but lack specific assessment tools and criteria.
- Existing tools such as the Khorana score have limitations and cannot comprehensively and accurately assess the VTE risk of all types of cancer patients.

2. **Application of new methods and technologies**:
- Explore new risk scores, nomograms, and assessment methods based on biomarkers and clinical features.
- Introduce the application of machine - learning algorithms in VTE risk assessment and their potential advantages.
- Analyze the application value of imaging and biomarker screening techniques in outpatient cancer patients.

3. **Challenges in clinical practice**:
- How to effectively select high - risk outpatient cancer patients who need primary prevention in clinical practice.
- Explore the impact of different tumor types and treatment regimens on VTE risk.
- Provide support for future research directions and clinical decision - making.

### Formula and chart descriptions

Some of the key formulas and charts involved in the article include:

- **Khorana score formula**:
\[
\text{Khorana score}=\sum_{i = 1}^{n}w_i x_i
\]
where \(w_i\) is the weight of each factor and \(x_i\) is the corresponding variable value (such as cancer type, blood test results, etc.).

- **Relationship between D - dimer level and VTE risk**:
\[
\text{VTE risk}\propto D\text{-dimer level}
\]
The article mentions that the D - dimer level is an important indicator for predicting VTE, and its optimal cut - off value is 4.0 µg/mL.

Through these contents, the paper aims to provide clinicians with more comprehensive and accurate VTE risk assessment tools to improve the management and prognosis of outpatient cancer patients.